carbamates has been researched along with darunavir in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (26.19) | 29.6817 |
| 2010's | 30 (71.43) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Bilcer, G; Boross, P; Devasamudram, T; Gaddis, L; Ghosh, AK; Harrison, RW; Kincaid, JF; Koh, Y; Maeda, K; Mitsuya, H; Nakata, H; Ogata, H; Tie, Y; Volarath, P; Wang, YF; Weber, IT | 1 |
| de Béthune, MP; King, NM; Nalivaika, EA; Prabu-Jeyabalan, M; Schiffer, CA; Wigerinck, P | 1 |
| Berthé, H; de Truchis, P; Delaugerre, C; Galperine, T; Long, K; Mathez, D; Peytavin, G | 1 |
| Chapsal, BD; Ghosh, AK; Mitsuya, H; Weber, IT | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| de Béthune, MP; De Meyer, S; Picchio, G | 1 |
| Bruzzone, B; Cenderello, G; Dentone, C; Di Biagio, A; Ferrea, G; Icardi, G; Mularoni, A; Rosso, R; Viscoli, C | 1 |
| Ali, A; Altman, MD; Anjum, SG; Cao, H; Chellappan, S; Fernandes, MX; Gilson, MK; Kairys, V; Nalam, MN; Rana, TM; Reddy, GS; Schiffer, CA; Tidor, B | 1 |
| Ghosh, AK; Kovalevsky, AY; Weber, IT | 1 |
| Louis, JM; Sayer, JM | 1 |
| Hidalgo Tenorio, C; Pasquau Liaño, J | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Baldridge, A; Ghosh, AK; Miguel, SG; Mitsuya, H; Rao, KV; Wang, YF; Weber, IT; Xu, CX | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Alvanzo, AA; Gruber, VA; Ma, Q; McCance-Katz, EF; Moody, DE; Morse, GD; Pade, PA; Prathikanti, S; Rainey, PM | 1 |
| Boross, PI; Chiu, TY; Ghosh, AK; Harrison, RW; Louis, JM; Tie, Y; Tozser, J; Wang, YF; Weber, IT | 1 |
| Bandaranayake, RM; King, NM; Mittal, S; Nalam, MN; Nalivaika, EA; Prabu-Jeyabalan, M; Schiffer, CA; Yilmaz, NK | 1 |
| Amano, M; Aoki, M; Campbell, JR; Das, D; Ghosh, AK; Mitsuya, H; Rao, KV; Salcedo-Gómez, PM; Tojo, Y; Xu, CX | 1 |
| Di Nicola, M; Falasca, K; Pizzigallo, E; Ucciferri, C; Vecchiet, J; Vignale, F | 1 |
| Agniswamy, J; Ghosh, AK; Louis, JM; Rao, KV; Sayer, JM; Shen, CH; Wang, YF; Weber, IT; Xu, CX | 1 |
| Leonis, G; Papadopoulos, MG; Steinbrecher, T | 1 |
| Amano, M; Das, D; Ghosh, AK; Mitsuya, H; Mizuno, A; Salcedo Gómez, PM; Yashchuk, S | 1 |
| Deeks, ED | 1 |
| Hillewaert, V; Hoetelmans, RM; Iterbeke, K; Kakuda, TN; Opsomer, M; Petrovic, R; Timmers, M; Van De Casteele, T | 1 |
| Aoki, M; Aoki-Ogata, H; Chang, SB; Das, D; Davis, DA; Desai, DV; Fyvie, WS; Garimella, H; Ghosh, AK; Kaufman, JD; Maeda, K; Mitsuya, H; Smith, DW; Wingfield, PT; Yedidi, RS | 1 |
| Hoetelmans, RM; Kakuda, TN; Neujens, M; Opsomer, M; Petrovic, R; Salih, H; Van De Casteele, T | 1 |
| Chen, J; Liang, Z; Wang, W; Yi, C; Zhang, Q; Zhang, S | 1 |
| Amano, M; Das, D; Ghosh, AK; Mitsuya, H; Nyalapatla, PR; Parham, GL; Salcedo-Gómez, PM; Tojo, Y | 1 |
| Agniswamy, J; Ghosh, AK; Louis, JM; Shen, CH; Weber, IT; Yashchuk, S | 1 |
| Shao, Q; Shi, J; Wang, J; Yu, Y; Zhu, W | 1 |
| Raines, RT; Windsor, IW | 1 |
| Alibés, A; Gil, V; Guallar, V; Hosseini, A; Noguera-Julian, M; Orozco, M; Paredes, R; Soliva, R | 1 |
| Cattaneo, D; D'Avolio, A; Gervasoni, C; Micheli, V; Milazzo, L; Sollima, S | 1 |
| Burger, DM; D'Avolio, A; Di Perri, G; Drenth, JP; Grintjes, K; Kanter, CT; Smolders, EJ; van Crevel, R | 1 |
| Amano, M; Bulut, H; Das, D; Delino, NS; Ghosh, AK; Mitsuya, H; Salcedo-Gómez, PM; Sheri, VR; Yedidi, RS; Zhao, R | 1 |
| Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D | 1 |
| Camproux, AC; Cano Contreras, ME; Descamps, D; Flatters, D; Regad, L; Triki, D; Visseaux, B | 1 |
| Chen, J; Peng, C; Wang, J; Zhu, W | 1 |
| Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
| Chao, CM; Hsueh, PR; Lai, CC | 1 |
6 review(s) available for carbamates and darunavir
| Article | Year |
|---|---|
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Topics: Carbamates; Darunavir; Drug Design; Drug Resistance, Viral; Furans; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Structure-Activity Relationship; Sulfonamides | 2008 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Treatment Outcome | 2008 |
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Molecular Structure; Ritonavir; Sulfonamides | 2008 |
Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Topics: Atazanavir Sulfate; Carbamates; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Synergism; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Thiazoles | 2014 |
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Carbamates; Cobicistat; COVID-19 Drug Treatment; Darunavir; Dibenzothiepins; Drug Combinations; Drug Therapy, Combination; Humans; Imidazoles; Indoles; Iran; Lopinavir; Morpholines; Pyrazines; Pyridones; Pyrrolidines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Triazines; Valine | 2021 |
6 trial(s) available for carbamates and darunavir
| Article | Year |
|---|---|
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.
Topics: Anti-HIV Agents; Area Under Curve; Buprenorphine; Carbamates; Darunavir; Drug Interactions; Female; Furans; Half-Life; History, 16th Century; History, 17th Century; Humans; Male; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides | 2012 |
Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
Topics: Adult; Biological Availability; Carbamates; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Combinations; Female; Healthy Volunteers; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Thiazoles; Young Adult | 2014 |
Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Cobicistat; Darunavir; Drug Combinations; Drug Monitoring; Female; Food; Healthy Volunteers; Humans; Male; Middle Aged; Sulfonamides; Therapeutic Equivalency; Thiazoles; Young Adult | 2014 |
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Anti-Retroviral Agents; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
30 other study(ies) available for carbamates and darunavir
| Article | Year |
|---|---|
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; CD4-Positive T-Lymphocytes; Cell Line; Crystallography, X-Ray; Darunavir; Drug Resistance, Multiple, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Sulfonamides; Virus Replication | 2003 |
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.
Topics: Binding Sites; Carbamates; Darunavir; Drug Resistance, Multiple, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Sulfonamides; Thermodynamics | 2004 |
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
Topics: Carbamates; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Viral Load | 2007 |
Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome | 2008 |
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.
Topics: Algorithms; Carbamates; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Models, Molecular; Structure-Activity Relationship; Sulfonamides | 2008 |
Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
Topics: Binding Sites; Carbamates; Darunavir; Furans; HIV Protease Inhibitors; HIV-1; Kinetics; Models, Molecular; Molecular Structure; Sulfonamides | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
Topics: Carbamates; Crystallography, X-Ray; Darunavir; Dimerization; Drug Design; Drug Resistance, Multiple, Viral; Furans; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Proteins; Structure-Activity Relationship; Sulfonamides | 2010 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
Topics: Amino Acid Sequence; Binding Sites; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Kinetics; Saquinavir; Sulfonamides | 2012 |
Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV-1; Humans; Kinetics; Models, Molecular; Mutant Proteins; Mutation, Missense; Oligopeptides; Point Mutation; Protein Binding; Protein Conformation; Pyridines; Sulfonamides; Thermodynamics | 2013 |
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Topics: Amino Acid Sequence; Atazanavir Sulfate; Binding Sites; Carbamates; Cell Line, Tumor; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Molecular Docking Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy.
Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Carbamates; CD4 Lymphocyte Count; Darunavir; Dyslipidemias; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolome; Middle Aged; Organophosphates; Prospective Studies; Protease Inhibitors; Ritonavir; Sulfonamides; White People | 2013 |
Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Topics: Binding Sites; Calorimetry, Differential Scanning; Carbamates; Crystallization; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; Escherichia coli; Furans; Genes, Synthetic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Pyrrolidinones; Structure-Activity Relationship; Sulfonamides | 2013 |
A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Topics: Anti-HIV Agents; Carbamates; Cluster Analysis; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen Bonding; Indinavir; Molecular Dynamics Simulation; Mutation; Protein Conformation; Saquinavir; Sulfonamides; Thermodynamics | 2013 |
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Topics: Animals; Astrocytes; Atazanavir Sulfate; Blood-Brain Barrier; Carbamates; Cell Line; Darunavir; Drug Resistance, Multiple, Viral; Endothelial Cells; Fluorides; Haplorhini; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Lopinavir; Models, Biological; Molecular Docking Simulation; Oligopeptides; Pericytes; Pyridines; Rats; Saquinavir; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
Topics: Carbamates; Catalytic Domain; Crystallization; Darunavir; Drug Resistance, Multiple, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Molecular Conformation; Molecular Sequence Data; Protein Folding; Pyridines; Pyrones; Sulfonamides; X-Ray Diffraction | 2014 |
Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
Topics: Carbamates; Catalytic Domain; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Hydrogen Bonding; Molecular Dynamics Simulation; Protein Binding; Protein Structure, Secondary; Sulfonamides; Thermodynamics | 2014 |
A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.
Topics: Blood-Brain Barrier; Carbamates; Darunavir; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides; Virus Replication | 2015 |
Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Topics: Carbamates; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Structure-Activity Relationship; Sulfonamides | 2015 |
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
Topics: Binding Sites; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Structure, Tertiary; Sulfonamides; Thermodynamics | 2015 |
Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
Topics: Carbamates; Darunavir; Fluorescence; Fluorescent Dyes; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Pyridines; Pyrones; Sulfonamides | 2015 |
Computational Prediction of HIV-1 Resistance to Protease Inhibitors.
Topics: Amino Acid Sequence; Carbamates; Computational Biology; Darunavir; Drug Evaluation, Preclinical; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Mutation; Protein Multimerization; Protein Structure, Quaternary; Sulfonamides | 2016 |
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.
Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
Topics: Anti-HIV Agents; Antiviral Agents; Area Under Curve; Carbamates; Coinfection; Darunavir; Diuretics; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidines; Renal Insufficiency; Ritonavir; Treatment Outcome; Valine | 2016 |
A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
Topics: Animals; Blood-Brain Barrier; Carbamates; Cell Line; Central Nervous System; Crystallography, X-Ray; Darunavir; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Viral; Ethylamines; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Peptides; Rats; Structure-Activity Relationship; Sulfonamides; Virus Replication | 2016 |
Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.
Topics: Carbamates; Crystallography, X-Ray; Darunavir; Enzyme Inhibitors; Furans; HIV Protease; Protein Binding; Protein Conformation; Protein Subunits; Sulfonamides | 2018 |
Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
Topics: Allosteric Regulation; Binding Sites; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen Bonding; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Sulfonamides; Thermodynamics | 2018 |